Pitcairn CO Mirati Therapeutics, Inc. Transaction History

Pitcairn CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $173,857 - $250,611	-1,317 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$132.13 - $177.45 $4,228 - $5,678	-32 Reduced 2.37%	1,317 $233,000
Q2 2021 Aug 11, 2021	SELL	$144.0 - $179.73 $11,520 - $14,378	-80 Reduced 5.6%	1,349 $218,000
Q1 2021 May 10, 2021	SELL	$158.92 - $221.61 $38,617 - $53,851	-243 Reduced 14.53%	1,429 $245,000
Q4 2020 Feb 05, 2021	SELL	$162.05 - $240.27 $64,333 - $95,387	-397 Reduced 19.19%	1,672 $367,000
Q3 2020 Nov 03, 2020	SELL	$113.26 - $167.27 $10,306 - $15,221	-91 Reduced 4.21%	2,069 $344,000
Q2 2020 Jul 28, 2020	BUY	$72.01 - $120.39 $155,541 - $260,042	2,160 New	2,160 $247,000
Q1 2020 May 13, 2020	SELL	$69.78 - $116.21 $114,997 - $191,514	-1,648 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$70.76 - $128.86 $116,612 - $212,361	1,648 New	1,648 $213,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Pitcairn CO, based on Form 13F filings with the SEC.

Stay updated on Pitcairn CO with notifications on news.